Please login to the form below

Not currently logged in
Email:
Password:

TB

This page shows the latest TB news and features for those working in and with pharma, biotech and healthcare.

GSK's pivotal TB vaccine could prevent millions of deaths

GSK's pivotal TB vaccine could prevent millions of deaths

GlaxoSmithKline has announced that its IAVI-partnered experimental tuberculosis (TB) vaccine candidate significantly reduced the occurrence of pulmonary tuberculosis disease. . ... the only available vaccine, BCF, not providing a proven and consistent

Latest news

  • J&J pledges $500m investment into HIV and tuberculosis R&D J&J pledges $500m investment into HIV and tuberculosis R&D

    In the TB therapy area, J&J will work with partners to improve detection methods for undiagnosed cases of the disease, and broaden the access to its targeted TB medicine bedaquiline – ... It also plans to accelerate R&D efforts to aid in the discovery

  • Gates’ non-profit biotech for poverty diseases sets out its stall at BIO Gates’ non-profit biotech for poverty diseases sets out its stall at BIO

    out research studies in western Kenya and her father’s battle with TB. ... number of avoidable deaths each year - 1.7m in the case of TB and around half a million apiece from malaria and diarrhoea/enteric diseases.

  • J&J expands its TB research programme J&J expands its TB research programme

    Johnson and Johnson (J&J) has partnered with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to develop new treatments for tuberculosis (TB). ... Paul Stoffels, chief scientific officer at

  • GSK unveils access plan for low-income countries GSK unveils access plan for low-income countries

    HIV, TB and hepatitis C drugs - "to help address the increasing burden of cancer in developing countries".

  • EU launches HIV action plan EU launches HIV action plan

    A three-year project to address the gaps and discrepancies in existing HIV, tuberculosis (TB) and viral hepatitis prevention has been launched in Europe. ... It also aims to implement a harm reduction programme as part an EU-wide strategy for the

More from news
Approximately 5 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    Also, the present situation is that some of the diseases with greatest global need for new efficacious treatments, such as HIV, TB, Malaria, have been difficult to address using classical approaches

  • The cultural construction of illness The cultural construction of illness

    For example, in the 21st century TB is seen exclusively as an appalling condition linked with poverty, whereas in the early 19th century, fashionable metropolitans tried to cultivate a pleasingly pale

  • Reactivating drug research programmes Reactivating drug research programmes

    One research-led breakthrough to hit the headlines involves the use of genome sequencing to isolate different strains of tuberculosis (TB), allowing the disease to be diagnosed more quickly.

  • Interview: Charles Mgone, EDCTP Interview: Charles Mgone, EDCTP

    We will ask them what areas they are interested in regarding our scope in HIV, TB, malaria and now neglected tropical diseases.”. ... Consider TB, for example. Clinical trials will have to take place in India and China.

  • Interview: Jane Griffiths, Janssen EMEA Interview: Jane Griffiths, Janssen EMEA

    The company also has programmes for providing not-for-profit drugs to the 40 poorest countries, particularly for HIV, as well as for TB in the near future with the development ... of its multi-resistant TB drug.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics